Cic edizioni internazionali
Clinical Dermatology

Retention rate of systemic drugs in patients with chronic plaque psoriasis

Original Article, 8 - 14
Tag this article
Abstract
Enhanced HTML Full text PDF
Introduction. The retention rate (RR) is the proportion of patients who maintain the same drug in a given time period, and it is a tool for evaluating the effectiveness and safety of treatments.
Objective. Estimate the RR of systemic drugs in reallife patients with chronic plaque psoriasis.
Methods. Retrospective evaluation of 392 adult patients with psoriasis who received a systemic drug, including methotrexate (n=158), cyclosporine (n=35), acitretin (n=24), infliximab (n=61), etanercept (n=76) and adalimumab (n=38). RR was evaluated using the
Kaplan-Meier survival data analysis in which the event was drug discontinuation due to inefficacy or intolerance with log-rank tests. Cox proportional-hazards regression model was also estimated.
Results. The RR at 24 and 30 months (but not at 12 months) for TNF-α blockers was higher than methotrexate, cyclosporine and acitretin (p<0.001). Main cause of drug discontinuation was intolerance. No differences in RR were detected among TNF-α
blockers. In multivariate analysis the predictors of early drug discontinuation were having received any conventional drugs versus any TNF-α blockers, higher body mass index (HR 1.91, 95% C.I. 1.68-2.1; p=0.008) and having previously been treated with
more than three systemic drugs (HR 1.37, 95% C.I. 1.10-1.79; p=0.032).
Conclusions. RR of TNF-α blockers was higher than conventional drugs. Discontinuation of conventional drugs was mostly due to intolerance. RR of systemic drugs was negatively influenced by obesity and by history of previous drug failure.

Vol. 5 (No. 1) 2017 January - March

  1. Unmet needs in hidradenitis suppurativa: patients’ perspective on daily management and cosmetic cares
    Atzori L., Pintori G., Patta F., Pinn A.L., Rongioletti F.
    doi: 10.11138/cderm/2017.5.1.001
  2. EP2311454 treatment for atopic dermatitis: therapeutic efficiency in patients and anti-inflammatory in vitro
    Umbert I., Sans G., Valls J., Márquez L., Costales P., Fernández L.
    doi: 10.11138/cderm/2017.5.1.005
  3. Cutaneous leishmaniasis and its clinical spectrum. An overview from the Old World
    Dassoni F.
    doi: 10.11138/cderm/2017.5.1.012
  4. Systemic immunosuppressive treatment in adult patients with atopic dermatitis: current and new treatment options
    van der Schaft J., Thijs J.L., Hijnen D., de Bruin-Weller M.S.
    doi: 10.11138/cderm/2017.5.1.022
  5. Possible role of mast cells and IL-37 in the pathogenesis of psoriasis
    Conti P., Caraffa A., Spinas E., Lessiani G., Kritas S.K., Ronconi G., Theoharides T.C.
    doi: 10.11138/cderm/2017.5.1.030
  6. Commentary on dermoscopy in general dermatology
    Russo T., Piccolo V., Agozzino M., Moscarella E., Lallas A., Argenziano G.
    doi: 10.11138/cderm/2017.5.1.037
  7. Gluten related disorders: even a dermatological issue
    Bonciolini V., Caproni M.
    doi: 10.11138/cderm/2017.5.1.043
  8. Congenital mastocytosis
    Virdi A., Neri I., Gurioli C., Patrizi A.
    doi: 10.11138/cderm/2017.5.1.048
  9. Frontal fibrosing alopecia: when the treatment is worse than the disease
    Lai M., Brundu M.A., Atzori L.
    doi: 10.11138/cderm/2017.5.1.060
Last Viewed articles: la lista degli ultimi x visitati.
  1. Retention rate of systemic drugs in patients with chronic plaque psoriasis
    Gisondi P., Tessari G., Di Mercurio M., Del Giglio M., Girolomoni G.
credits